1st Jul 2019 12:02
(Alliance News) - Renalytix AI PLC on Monday said it has been granted a CPT proprietary laboratory analyses code for KidneyIntelX in the US.
Shares in Renalytix were up 8.0% at 324.00 pence in trading at noon.
KidneyIntelX is intended to improve the identification and management of type 2 diabetics who have fast-progressing kidney disease. In a recent study, KidneyIntelX's algorithms successfully improved predictions for whether a patient was likely to suffer rapid kidney function decline.
"This is an important step as we prepare for KidneyIntelX's scaled roll-out in the US. A CPT code is instrumental in obtaining insurance coverage and reimbursement, and will increase access to KidneyIntelX testing results for patients with chronic kidney disease," said Renalytix Chief Medical Officer Michael Donovan.
The code was granted by the American Medical Association and will become effective at the start of October. Renalytix noted that "CPT terminology is the most common medical nomenclature" in the US for reporting medical, surgical, and other services for public and private health insurance programmes.
Related Shares:
Renalytix Plc